752 related articles for article (PubMed ID: 28842994)
1. Safety and immunogenicity of the novel seasonal preservative- and adjuvant-free influenza vaccine: Blind, randomized, and placebo-controlled trial.
Sarsenbayeva G; Volgin Y; Kassenov M; Issagulov T; Bogdanov N; Sansyzbay A; Abitay R; Nurpeisova A; Sagymbay A; Koshemetov Z; Stukova M; Buzitskaya Z; Кulmagambetov I; Karabayeva D; Davlyatshin T; Khairullin B
J Med Virol; 2018 Jan; 90(1):41-49. PubMed ID: 28842994
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and safety of a novel seasonal influenza preservative-free vaccine manufactured in Kazakhstan: Results of a randomized, comparative, phase II clinical trial in adults.
Sarsenbayeva G; Volgin Y; Kassenov M; Issagulov T; Bogdanov N; Sansyzbay A; Stukova M; Buzitskaya Z; Кulmagambetov I; Davlyatshin T; Khairullin B
Hum Vaccin Immunother; 2018 Mar; 14(3):609-614. PubMed ID: 29112488
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of a seasonal trivalent inactivated split influenza vaccine: a phase I randomized clinical trial in healthy Serbian adults.
Stevanovic G; Lavadinovic L; Filipovic Vignjevic S; Holt R; Ilic K; Berlanda Scorza F; Sparrow E; Stoiljkovic V; Torelli G; Madenwald T; Socquet M; Barac A; Ilieva-Borisova Y; Pelemis M; Flores J
Hum Vaccin Immunother; 2018 Mar; 14(3):579-586. PubMed ID: 29239682
[TBL] [Abstract][Full Text] [Related]
4. Safety, immunogenicity and cross-reactivity of a Northern hemisphere 2013-2014 seasonal trivalent inactivated split influenza virus vaccine, Anflu®.
Shen Y; Hu Y; Meng F; Du W; Li W; Song Y; Ji X; Huo L; Fu Z; Yin W
Hum Vaccin Immunother; 2016 May; 12(5):1229-34. PubMed ID: 26934750
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and safety of an inactivated 2012/2013 trivalent influenza vaccine produced in mammalian cell culture (Optaflu®): an open label, uncontrolled study.
Vinnemeier CD; Fischer-Herr J; Meyer S; Liebig K; Theeß W; Burchard GD; Cramer JP
Hum Vaccin Immunother; 2014; 10(2):441-8. PubMed ID: 24240428
[TBL] [Abstract][Full Text] [Related]
6. Phase IV: randomized controlled trial to evaluate lot consistency of trivalent split influenza vaccines in healthy adults.
Song JY; Cheong HJ; Lee J; Wie SH; Park KH; Kee SY; Jeong HW; Kim YS; Noh JY; Choi WS; Park DW; Sohn JW; Kim WJ
Hum Vaccin Immunother; 2014; 10(10):2958-64. PubMed ID: 25483462
[TBL] [Abstract][Full Text] [Related]
7. Immunological persistence of a seasonal influenza vaccine in people more than 3 years old.
Bai Y; Shi N; Lu Q; Yang L; Wang Z; Li L; Han H; Zheng D; Luo F; Zhang Z; Ai X
Hum Vaccin Immunother; 2015; 11(7):1648-53. PubMed ID: 26083828
[TBL] [Abstract][Full Text] [Related]
8. A phase 2/3 double-blind, randomized, placebo-controlled study to evaluate the safety and immunogenicity of a seasonal trivalent inactivated split-virion influenza vaccine (IVACFLU-S) in healthy adults in Vietnam.
Lan PT; Toan NT; Thang HA; Thang TC; Be LV; Thai DH; Huong VM; Nga NT; Tang Y; Holt R; Francesco BS; Flores J; Tewari T
Hum Vaccin Immunother; 2019; 15(12):2933-2939. PubMed ID: 31070986
[No Abstract] [Full Text] [Related]
9. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine in healthy adults: a phase II, open-label, uncontrolled trial in Japan.
Tsurudome Y; Kimachi K; Okada Y; Matsuura K; Ooyama Y; Ibaragi K; Kino Y; Ueda K
Microbiol Immunol; 2015 Oct; 59(10):597-604. PubMed ID: 26272602
[TBL] [Abstract][Full Text] [Related]
10. A reduced-dose seasonal trivalent influenza vaccine is safe and immunogenic in adult and elderly patients in a randomized controlled trial.
Vajo Z; Tamas F; Jankovics I
Clin Vaccine Immunol; 2012 Mar; 19(3):313-8. PubMed ID: 22219315
[TBL] [Abstract][Full Text] [Related]
11. Live attenuated seasonal and pandemic influenza vaccine in school-age children: a randomized controlled trial.
Klick B; Durrani S; Chan KH; Ip DK; Chou ES; Kwok HK; Ng S; Chiu SS; Peiris JS; Leung GM; Cowling BJ
Vaccine; 2013 Apr; 31(15):1937-43. PubMed ID: 23434387
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of trivalent inactivated influenza vaccine in adults 60 years of age and older: a phase II, a randomized, comparative trial in Kazakhstan.
Sarsenbayeva G; Issagulov T; Kassenov M; Abitay R; Orynbayev M; Stukova M; Pisareva M; Davlyatshin T; Lespek K; Khairullin B
Hum Vaccin Immunother; 2020 Aug; 16(8):1791-1797. PubMed ID: 32048890
[TBL] [Abstract][Full Text] [Related]
13. Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trial.
Vesikari T; Kirstein J; Devota Go G; Leav B; Ruzycky ME; Isakov L; de Bruijn M; Oberye J; Heijnen E
Lancet Respir Med; 2018 May; 6(5):345-356. PubMed ID: 29631857
[TBL] [Abstract][Full Text] [Related]
14. Clinical trial to evaluate the safety and immunogenicity of a trivalent surface antigen seasonal influenza vaccine produced in mammalian cell culture and administered to young and elderly adults with and without A(H1N1) pre-vaccination.
Loebermann M; Voss U; Meyer S; Bosse D; Fritzsche C; Klammt S; Frimmel S; Riebold D; Reisinger EC
PLoS One; 2013; 8(8):e70866. PubMed ID: 23976960
[TBL] [Abstract][Full Text] [Related]
15. Intradermally-administered influenza virus vaccine is safe and immunogenic in healthy adults 18-64 years of age.
Gorse GJ; Falsey AR; Fling JA; Poling TL; Strout CB; Tsang PH
Vaccine; 2013 May; 31(19):2358-65. PubMed ID: 23499604
[TBL] [Abstract][Full Text] [Related]
16. Safety, tolerability, and immunogenicity of influenza vaccination with a high-density microarray patch: Results from a randomized, controlled phase I clinical trial.
Forster AH; Witham K; Depelsenaire ACI; Veitch M; Wells JW; Wheatley A; Pryor M; Lickliter JD; Francis B; Rockman S; Bodle J; Treasure P; Hickling J; Fernando GJP
PLoS Med; 2020 Mar; 17(3):e1003024. PubMed ID: 32181756
[TBL] [Abstract][Full Text] [Related]
17. Combined, concurrent, and sequential administration of seasonal influenza and MF59-adjuvanted A/H5N1 vaccines: a phase II randomized, controlled trial of immunogenicity and safety in healthy adults.
Lopez P; Caicedo Y; Sierra A; Tilman S; Banzhoff A; Clemens R
J Infect Dis; 2011 Jun; 203(12):1719-28. PubMed ID: 21606530
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of a trivalent single dose seasonal influenza vaccine containing pandemic A(H1N1) antigen in younger and elderly subjects: a phase III open-label single-arm study.
Loebermann M; Anders G; Brestrich G; Fritzsche C; Klammt S; Boršo D; Frimmel S; Riebold D; Reisinger EC
Vaccine; 2011 Feb; 29(6):1228-34. PubMed ID: 21167116
[TBL] [Abstract][Full Text] [Related]
19. Influenza vaccination in children primed with MF59-adjuvanted or non-adjuvanted seasonal influenza vaccine.
Vesikari T; Forstén A; Arora A; Tsai T; Clemens R
Hum Vaccin Immunother; 2015; 11(8):2102-12. PubMed ID: 26091244
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity of a 2009 pandemic influenza virus A H1N1 vaccine, administered simultaneously with the seasonal influenza vaccine, in children receiving chemotherapy.
Ottóffy G; Horváth P; Muth L; Sólyom A; Garami M; Kovács G; Nyári T; Molnár D; Pauler G; Jankovics I
Pediatr Blood Cancer; 2014 Jun; 61(6):1013-6. PubMed ID: 24395342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
